Juvenile autoimmune hepatitis: A comprehensive review.

Area of Science:

• Hepatology
• Immunology
• Internal Medicine

Background:

• Autoimmune hepatitis (AIH) is a rare, chronic liver disease affecting all age groups, likely triggered by environmental factors in genetically susceptible individuals.
• Clinical presentation varies widely, from asymptomatic cases to fulminant liver failure, with children often showing symptoms similar to acute hepatitis.

Purpose of the Study:

• To summarize the diagnosis, characteristic autoantibodies (ANA, SMA, LKM1, LC1), and histological findings of AIH.
• To outline current treatment strategies, including immunosuppression with steroids and azathioprine, and management of refractory cases.
• To highlight the role of liver transplantation and the potential for disease recurrence.

Main Methods:

• Diagnosis relies on elevated transaminases and immunoglobulin G (IgG) levels, circulating autoantibodies, and characteristic interface hepatitis on biopsy.
• Distinguishing between Type 1 AIH (ANA/SMA positive) and Type 2 AIH (LKM1/LC1 positive), with Type 2 being more common in children and presenting acutely.
• Reviewing the efficacy of standard immunosuppressive therapy and alternative treatments for non-responders.

Main Results:

• The majority of AIH patients achieve clinical and biochemical remission with standard immunosuppressive therapy.
• Second-line drugs offer variable results for patients intolerant or unresponsive to initial treatment.
• Liver transplantation is a life-saving option for end-stage liver disease, though AIH recurrence is a possibility.

Conclusions:

• Understanding AIH pathogenesis is crucial for developing novel, effective, and less toxic therapies.
• Personalized treatment regimens tailored to individual patients are essential for optimal outcomes.
• Further research into AIH mechanisms can lead to improved therapeutic strategies and management protocols.